including semaglutide branded as Wegovy or Ozempic, and tirzepatide (dual GIP/GLP-1 receptor agonist) branded as Zepbound or Mounjaro, for the management of obesity, type 2 diabetes, and other metabolic conditions increases, so too does the need to assess the advantages and potential downsides of long-term use
They are intended for general informational purposes only and do not constitute a medical guarantee or promise of outcome
ALWAYS consult your healthcare provider before starting, stopping, or changing any treatment plan
From basic biology to translational breakthroughs, these tools enable deeper investigations into GLP-1 signaling in metabolism and beyond
Bucinskaite V, Tolessa T, Pedersen J, et al
Chrysalin and teriparatide are two commercially available drugs that have been investigated as potential candidates in the upregulation of bone healing response in humans [28]